NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in Sidoti’s Micro-Cap Virtual Conference taking place August 16-17, 2023. Management will be presenting a corporate overview on August 17 at 10:00am Eastern time and will be hosting one-on-one meetings with investors.
The presentation will be webcast live and available for replay in the Investors section of LifeMD’s website by clicking here. To register for the conference, visit www.sidoti.com/events. Registration is free and investors are not required to be a Sidoti client.
About LifeMD™
LifeMD is a direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.
Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.26 |
| Daily Change: | 0.10 1.23 |
| Daily Volume: | 1,340,365 |
| Market Cap: | US$348.490M |
April 28, 2025 March 10, 2025 March 06, 2025 November 07, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
